Company: RGNT
Filing Date: 2025-01-27
Form Type: DRS/A
Source: 0001213900-25-006676
Chunk: 183

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-01-27
Form: DRS/A
Chunk 183
---

and cost. Effective as of the consummation of this offering, the maximum amount set forth in such agreements is (1) with respect to indemnification
in connection with a public offering of our securities, the gross proceeds raised by us and/or any selling shareholder in such public
offering, and (2) with respect to all permitted indemnification, the greater of (i) an amount equal to 25% of our shareholders’
equity, based on our most recent financial statements made publicly available before the date on which the indemnity payment is made
and (ii) $20 million. In the opinion of the SEC, indemnification of directors and executive officers for liabilities arising under the
Securities Act however, is against public policy and therefore unenforceable.

<div align='center'>112</div>

A shareholder’s investment
may be adversely affected to the extent we pay the costs of settlement and damage awards against officers and directors pursuant to these
indemnification provisions. We believe that these provisions, the insurance and the indemnity agreements are necessary to attract and
retain talented and experienced officers and directors.

Equity Incentive Plan

2009 Option Plan

We adopted our 2009 Option
Plan, or 2009 Plan, in January 2009 and it is scheduled to expire in December 2029. The 2009 Plan provides for the grant of options to
our employees, directors, officers, consultants, advisors, suppliers, and any other person or entity whose services are considered valuable.
As of November 1, 2024, options to purchase 31,716 Ordinary Shares were outstanding and 63,570 additional Ordinary Shares available for
future issuance. Of such outstanding options, options to purchase 31,716 Ordinary Shares were vested as of December 31, 2023, with an
exercise price of $ 9.933 per share.

The 2009 Plan provides for
options to be granted at the determination of our board of directors (which is entitled to delegate its powers under the 2009 Plan to
our compensation committee) subject to applicable laws. Upon termination of employment for any reason, other than in the event of death
or disability or for cause, all unvested options will expire and all vested options at time of termination will generally be exercisable
for 90 days following termination, subject to the terms of the 2009 Plan and the governing option agreement. If we terminate a grantee’s
employment or engagement for